Clinical Trials /

Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC

NCT02454842

Description:

This phase 2 study is designed to evaluate the safety and activity of TH-4000 (Tarloxotinib), a hypoxia-activated prodrug, in patients with EGFR-Mutant, T790M-Negative, Advanced non-small cell lung cancer (NSCLC).

Related Conditions:
  • Non-Small Cell Lung Carcinoma
Recruiting Status:

Terminated

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC
  • Official Title: A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor

Clinical Trial IDs

  • ORG STUDY ID: TH-CR-601
  • NCT ID: NCT02454842

Conditions

  • Non-small Cell Lung Cancer
  • NSCLC
  • Non-squamous NSCLC

Interventions

DrugSynonymsArms
TH-4000 (Tarloxotinib)TH-4000 (Tarloxotinib)

Purpose

This phase 2 study is designed to evaluate the safety and activity of TH-4000 (Tarloxotinib), a hypoxia-activated prodrug, in patients with EGFR-Mutant, T790M-Negative, Advanced non-small cell lung cancer (NSCLC).

Detailed Description

      A single arm open label multi-center Phase 2 study in which the pharmacokinetics, safety,
      tolerability and efficacy of TH-4000 (Tarloxotinib) will be assessed in patients with EGFR
      mutant, T790M negative advanced NSCLC. Patients must have demonstrated progression during
      EGFR TKI therapy.

      Hypoxia PET scans will be obtained in select centers to analyze potential predictors of tumor
      response.
    

Trial Arms

NameTypeDescriptionInterventions
TH-4000 (Tarloxotinib)ExperimentalTH-4000 (Tarloxotinib), 150 mg/m2 will be administered by IV infusion on Days 1, 8, 15, and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity
  • TH-4000 (Tarloxotinib)

Eligibility Criteria

        Key Eligibility Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Confirmed recurrent Stage IV NSCLC which progressed while on treatment with EGFR TKI

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors version
             1.1 (RECIST 1.1)

          -  Documented evidence of an EGFR mutation known to be associated with an EGFR TKI
             sensitivity

          -  No T790M mutation or small cell transformation including an assessment from tumor
             biopsy obtained while on or subsequent to the most recent EGFR TKI therapy

          -  Acceptable laboratory results as indicated by protocol

          -  Acceptable cardiac function as indicated by protocol

        Key Exclusion Criteria:

          -  Receiving medication that prolongs QT interval, with a risk of causing Torsades de
             Pointes (TdP) unless ECG meets inclusion criteria while on a stable dose of the
             medication

          -  Family history of long QTc syndrome

          -  Symptomatic central nervous system (CNS) lesions

          -  Radiation therapy within 2 weeks prior to the first dose of study medication

          -  Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose
             of study medication

          -  Concurrent active malignancy requiring systemic treatment

          -  Any other serious uncontrolled medical disorders or psychological conditions that may
             interfere with study conduct including but not limited to: clinically significant
             active infection (e.g., tuberculosis, viral hepatitis, human immunodeficiency virus
             [HIV]), recent (within 6 months) myocardial infarction or unstable angina, congestive
             heart failure, poorly-controlled hypertension or diabetes, concurrent active
             malignancy, or psychiatric condition that may interfere with the patient's ability to
             follow study procedures

          -  Pregnant or breast-feeding
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Number of participants with response rate as evaluated by RECIST criteria
Time Frame:Approximately 12 months
Safety Issue:
Description:

Secondary Outcome Measures

Measure:Incidence of adverse events (AEs)
Time Frame:Up to 30 days after last dose
Safety Issue:
Description:
Measure:Type of adverse events (AEs)
Time Frame:Up to 30 days after last dose
Safety Issue:
Description:
Measure:Severity of adverse events (AEs)
Time Frame:Up to 30 days after last dose
Safety Issue:
Description:
Measure:Duration of response (DOR) calculated for all patients achieving an objective response
Time Frame:Approximately 12 months
Safety Issue:
Description:
Measure:Progression-free survival (PFS)
Time Frame:Approximately 12 months
Safety Issue:
Description:
Measure:Overall Survival (OS)
Time Frame:Approximately 12 months
Safety Issue:
Description:
Measure:Time to peak plasma concentration (Tmax)
Time Frame:Cycle 1 Day 1 predose and up to 24 hours post dose
Safety Issue:
Description:Time to peak plasma concentration (Tmax), maximum plasma concentration (Cmax), area under concentration-time curve (AUC)
Measure:Maximum plasma concentration (Cmax)
Time Frame:Cycle 1 Day 1 predose and up to 24 hours post dose
Safety Issue:
Description:
Measure:Area under concentration-time curve (AUC)
Time Frame:Cycle 1 Day 1 predose and up to 24 hours post dose
Safety Issue:
Description:
Measure:QTc Interval
Time Frame:Screening, Cycle 1 Day 1, 8, 15 & 22, Day 1 of subsequent cycles
Safety Issue:
Description:

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Terminated
Lead Sponsor:Threshold Pharmaceuticals

Trial Keywords

  • TH-4000
  • low-oxygen conditions
  • hypoxia
  • non-small cell lung cancer
  • NSCLC
  • squamous cell carcinoma
  • Tarloxotinib

Last Updated

February 27, 2017